{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '2.', 'TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF', 'FIGURES', 'TABLE OF CONTENTS', '1.', 'SYNOPSIS', '4', '2.', 'TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES', '11', '3.', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', '16', '4.', 'INTRODUCTION', '18', '4.1.', 'Background Information', '18', '4.2.', 'Description of Study Drug', '19', '4.3.', 'Nonclinical Experience', '20', '4.4.', 'Clinical Experience', '21', '4.5.', 'Benefit-Risk Assessment', '24', '5.', 'STUDY OBJECTIVES AND PURPOSE', '25', '5.1.', 'Primary Objective', '25', '5.2.', 'Secondary Objective', '26', '5.3.', 'Exploratory Objective', '26', '6.', 'INVESTIGATIONAL PLAN', '26', '6.1.', 'Overall Study Design', '26', '6.1.1.', 'Rationale for Study Design, Dose(s) and Comparator(s)', '30', '6.1.2.', 'Estimated Duration of Subject Participation', '30', '6.2.', 'Number of Subjects', '30', '6.3.', 'Treatment Assignment', '30', '6.4.', 'Dose Adjustment Criteria', '30', '6.5.', 'Criteria for Study Termination', '30', '6.6.', 'End of the Study', '31', '7.', 'SELECTION AND WITHDRAWAL OF SUBJECTS', '31', '7.1.', 'Subject Inclusion Criteria', '31', '7.2.', 'Subject Exclusion Criteria', '32', '7.3.', 'Randomization Criteria (at the Randomization Visit (RV) - Visit 2):', '35', '7.4.', 'Subject Withdrawal Criteria', '35', '7.4.1.', 'Lost to Follow-up', '36', '7.4.2.', 'Permanent Discontinuation of Study Drug', '37', 'Glenmark', 'CONFIDENTIAL', 'Page 11 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '7.4.3.', 'Replacement of Subjects', '37', '8.', 'TREATMENT OF SUBJECTS', '37', '8.1.', 'Description of Study Drug', '37', '8.2.', 'Prior and Concomitant Medications', '38', '8.2.1.', 'Exclusion of Concomitant Medications', '39', '8.2.2.', 'Permitted Concomitant Medications', '39', '8.2.3.', 'Rescue Medication', '39', '8.2.4.', 'Lifestyle and/or Dietary Restrictions', '40', '8.3.', 'Treatment Compliance', '40', '8.3.1.', 'Treatment of Investigational Product Overdose', '40', '8.4.', 'Randomization and Blinding', '40', '8.4.1.', 'Unblinding in the Event of a Medical Emergency', '41', '8.5.', 'Subject Completion', '41', '9.', 'STUDY DRUG MATERIALS AND MANAGEMENT', '42', '9.1.', 'Study Drug', '42', '9.1.1.', 'Identity of Study Drug', '42', '9.1.1.1.', 'Chemical Name and Structural Formulas', '42', '9.1.1.2.', 'Mometasone Furoate', '42', '9.1.2.', 'Placebo', '42', '9.2.', 'Study Drug Packaging and Labeling', '43', '9.3.', 'Study Drug Storage', '43', '9.4.', 'Study Drug Preparation', '43', '9.5.', 'Administration', '43', '9.6.', 'Study Drug Accountability', '43', '9.7.', 'Study Drug Handling and Disposal', '44', '10.', 'ASSESSMENT OF EFFICACY', '44', '10.1.', 'Subject-Reported Nasal Symptoms', '44', '10.2.', 'Subject-Reported Non-Nasal Symptoms', '45', '10.3.', 'Physician Assessment of Nasal Symptom Severity', '46', '10.4.', 'Pediatric Rhinoconjuntivitis Quality of Life Questionnaire (PRQLQ)', '46', '11.', 'ASSESSMENT OF SAFETY', '47', '11.1.', 'Safety Parameters', '47', '11.1.1.', 'Demography', '47', 'Glenmark', 'CONFIDENTIAL', 'Page 12 of 90']\n\n###\n\n", "completion": "END"}